A trifocal diffractive intraocular lens (FineVision IOL, PhysIOL) reduces spectacle dependence after cataract surgery and provides patient satisfaction.
Chicago-A trifocal diffractive lens (FineVision IOL, PhysIOL) reduces spectacle dependence after cataract surgery and provides good patient satisfaction with uncorrected visual capabilities for near, intermediate, and distance tasks. Sunil Shah, FRCS(Ed), FRCOphth, reported the results of a pilot study at the annual meeting of the American Society of Cataract and Refractive Surgery.
This intraocular lens (IOL) is composed of two diffractive structures, according to Prof. Shah. The first diffractive structure adds about 3.5 D for near vision and the second 1.75 D for intermediate vision.
Prof. Shah, who is a visiting professor, University of Aston, Birmingham, UK, and colleagues conducted a study that included 20 patients who underwent bilateral implantation of the IOL. Prof. Shah performed all of the surgical procedures. The primary goal of the study was to examine visual outcomes following bilateral implantation of the IOL.
At 3 months postoperatively, the mean uncorrected postoperative monocular distance logarithm of the minimum angle of resolution (logMAR) visual acuity (VA) was 0.24 (20/20 = 0.0), the mean spherical equivalent 0.02, the mean logMAR best-corrected distance monocular (BCDVA) 0.12, and the mean logMAR binocular BCDVA 0.09, Prof. Shah said.
Following surgery, the patients were asked to complete a questionnaire to measure satisfaction. The questionnaire was specifically validated for use with patients with accommodative and multifocal IOLs to assess their level of visual independence. The responses to the quality of the VA could range from 0 to 4, with 0 indicating complete satisfaction and 4 indicating completely unsatisfied.
“The overall patient satisfaction at 3 months after implantation was 0.9 ± 0.9, a result that is very similar to all the new multifocal IOLs being introduced,” according to Prof. Shah.
Regarding the defocus curve, the investigators found that the IOL maintained a moderate level of VA 3 months postoperatively, which was better than that at all levels of defocus, he explained.
“This intraocular lens provides a clear area of intermediate VA not seen with other multifocal IOLs,” he said.
“The Fine Vision trifocal IOL works extremely well at three levels of VA and provides good patient satisfaction with uncorrected vision,” Prof. Shah concluded.
Prof. Shah has no financial interest in this subject matter.
For more articles in this issue of Ophthalmology Times eReport, click here.